Defunct Company
Total Trials
22
As Lead Sponsor
17
As Collaborator
5
Total Enrollment
1,497
NCT00050648
To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris
Phase: Phase 1/2
Role: Collaborator
Start: Oct 31, 1997
Completion: Apr 30, 2008
NCT00050661
To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris
NCT00006045
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia
Phase: Phase 3
Role: Lead Sponsor
Start: Mar 31, 2000
Completion: Not specified
NCT00198146
Prevention of Diabetes Progression Trial (PDPT)
Phase: Phase 2
Start: Jul 31, 2000
Completion: Feb 23, 2007
NCT00024544
Pilot Study in Patients With Symptomatic Steroid-Naive Asthma
Start: Aug 31, 2001
Completion: Feb 28, 2003
NCT00028288
Study of Daclizumab in Patients With Chronic, Persistent Asthma
Start: Sep 30, 2001
Completion: Dec 31, 2003
NCT00032292
Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease
Start: Mar 31, 2002
Completion: Aug 31, 2006
NCT00032305
Research Study in Patients With Severe Ulcerative Colitis
Phase: Phase 2/3
Completion: Nov 30, 2005
NCT00072943
A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease
Completion: Apr 30, 2004
NCT00032279
Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease
NCT00073047
Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis
Start: Apr 30, 2003
Completion: Jul 31, 2006
NCT00267306
Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis
Start: Jan 31, 2004
Completion: Dec 31, 2006
NCT00267709
Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease
Start: Feb 28, 2005
NCT00267722
Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease
NCT00279422
A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
Start: Feb 28, 2006
Completion: Aug 31, 2007
NCT00279435
Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study
Start: Aug 31, 2006
NCT00425347
Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma
Phase: Phase 1
Start: Dec 31, 2006
Completion: Jul 31, 2009
NCT00516841
A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer
Start: Aug 31, 2007
NCT00528827
A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension
Start: Sep 30, 2007
Completion: Dec 31, 2008